Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
B2 awesome even better in the written word.
EXMEX, - agreed. It sure as hell isn't France :)
B2HSL, they did state launch before the end of the month with co-prep. The particular European market that they mentioned in the video could be Germany. Novacyt have already reported that sales are strong into private labs over there.
Thanks BH2SH2 , great write up.
Exmex thx
I didn't find co-prep mentioned on the below link EXMEX, it is due to launch this month I think?
Link to the Lab Innovations page.
https://www.lab-innovations.com/exhibitor/novacyt-group/
Glad I'm not short this weekend, - somebody else's headache ha ha!!
Kevin Crittenton (3:19)
Novacyt is a technology leader with excellent products, and our contribution to the global pandemic has shown that we can make a larger mark in the diagnostic industry. The Americas is an important market for us. Naturally we want to grow our business here. In the future we will have a US commercial operations with more resources. We also have a direct sales force that will be focussing on expanding our distributor network.
And we will also have a larger product portfolio that is regulatory approved in the US and South America.
Graham Mullis (3:58)
The diagnostic market is a very large and an important part of the overall healthcare market. And in fact, it is highly fragmented and there are some significant unmet needs within those markets, which we can focus on.
Paul Oladimeji (4:12)
One of the biggest challenges that faces clinicians and the testing laboratories is the turnaround for the patient sample being turned into a result.
Novacyt are at the forefront of delivering near patient testing solutions, which reduce the need for the elaborate infrastructure that is required by those centralised laboratories. Now, this does'nt have to solely be for Covid-19. We're also working to apply this to fields like transplantation and other niche fields like antimicrobial resistance pathogens. This is how Novacyt can apply these innovations in other public health challenges.
Gemma Stokes (4:53)
Sequencing technology has advanced hugely in the last decade. So one project we're looking into is speeding up nucleic acid detection from around an hour to about ten minutes. The other project is so that we can detect more assays in one tube, which will give a lot more flexibility to our customers. Of course our surveillance programme will continue, but we're also looking at ways of automating that completely so that we can focus on these other projects.
Kevin Crittenton (5:24)
What I'm excited about is being a part of the Novacyt family and legacy in bringing innovative technology to the market place and being able to make a difference in the diagnostic market and the way that we can help to improve healthcare.
Graham Mullis (5:45)
The challenge for the business as we continue to grow is to ensure that it maintains at it's heart those core values of being nimble, being dynamic and really driving this can do attitude.
Whilst that will be supplemented by lots of structure as the business grows, that will remain the heart of Novacyt today and tomorrow.
Graham Mullis:
Novacyt is a global developer and manufacturer of clinical diagnostic products. The markets that we focus on today include infectious diseases and more specifically, respiratory and transplantation markets. We've been at the centre of a number of epidemics and pandemics around the world. And then of course more recently with Covid-19. So our ability to respond very quickly to the market is the reason why we were able to be one of the first companies to bring a fully qualified Covid-19 test to the market.
Guillermo Raimondo (0:44)
We have a full range of Covid-19 solutions from previous technologies like PCR, LFT and ELISA, that we can deploy easily for other infectious diseases. Our spectrum of customers is wide ranging from world government to private health care to laboratories big and small. And we through our global network, were able to ship our products to over 140 countries worldwide.
Paul Oladimeji (1:11)
Novacyt has a very extensive range of products, including human pathogen detection, veterinary and agriculture testing, oncology and genotyping, just to name a few. What makes these products unique is the high - advanced in silico analysis, which includes mutation modelling and analysis sequence structures. All of this is the foundation of our molecular diagnostics.
One of the key aspects of product development to the Novacyt group is our bioinformatics department. - Now they are not only responsible for the initial stages of our product development activities, but when the product is launched and it's in the market place, they're responsible for our post market surveillance.
GEMMA STOKES (2:05)
The bioinformatics team played a vital role in responding to the pandemic. We designed the original and I think the first commercially available assay to target this new coronavirus.
And we needed to be absolutely sure that a mutation wasn't going to arise within the primers or probes of that assay. So we developed one of the most comprehensive genome surveillance programmes in the diagnostic industry to check the sequences daily that we put onto the database to ensure that our assay would still work. And to date we have analysed over two million sequences.
What we've seen is unprecedented amounts of sequence information being made publically available. And going forward this is going to put the clinical diagnostic industry in a much stronger position to deal with emerging diseases and making sure we have the right tools and the right information to help combat any future pandemics.
Guillermo Raimondo (3:06)
The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets.